Esophageal Cancer Market Set to Surge at a 6.0% CAGR Through 2036: Immunotherapy and Targeted Therapies Reshape the Treatment Landscape

DelveInsight's, "Esophageal Cancer Market Insights, Epidemiology and Market Forecast - 2036" report provides comprehensive insights about the Esophageal Cancer market size, historical and forecasted epidemiology, current treatment practices, emerging therapies, and market opportunity across the 7MM (the United States; EU4 - Germany, France, Italy, and Spain; the United Kingdom; and Japan).

Download DelveInsight's comprehensive Esophageal Cancer Market Report to explore emerging therapies, key players, and future treatment landscapes @ https://www.delveinsight.com/report-store/esophageal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Key Takeaways from the Esophageal Cancer Market Report
• In November 2025, the US Food and Drug Administration (FDA) approved durvalumab (IMFINZI, AstraZeneca) in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single-agent durvalumab, for adults with resectable gastric or gastroesophageal junction adenocarcinoma.
• In August 2024, zolbetuximab (VYLOY) was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with stomach or gastro-esophageal junction cancer.
• According to DelveInsight estimates, the Esophageal Cancer Therapeutics Market Size in the 7MM was approximately USD 1,300 million in 2025 and is projected to grow at a CAGR of 6.0% between 2026 and 2036.
• The United States accounted for the highest Esophageal Cancer Therapeutics Market Size in 2025, at approximately USD 600 million, with recent analyses suggesting potential upside driven by increasing adoption of novel and targeted therapies.
• The total incident cases of Esophageal Cancer across the 7MM were approximately 79,000 in 2025.
• The leading Esophageal Cancer Companies include Jazz Pharmaceuticals, ZymeWorks, Amgen, Bayer, Eli Lilly and Company, Innovent, BeiGene, Apexigen, AstraZeneca, Bristol-Myers Squibb Company, Merck, AbbVie, and others.
• Promising Esophageal Cancer Therapies such as Tislelizumab (TEVIMBRA), Telisotuzumab adizutecan (Temab-A), Durvalumab (IMFINZI), Pembrolizumab (KEYTRUDA), Nivolumab (OPDIVO), Ramucirumab (CYRAMZA), Larotrectinib (VITRAKVI), Zanidatamab, Bemarituzumab, and others.

Access DelveInsight's in-depth Esophageal Cancer Market Analysis for a closer look at promising breakthroughs @ https://www.delveinsight.com/report-store/esophageal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Esophageal Cancer Overview
The Esophageal Cancer Market Report provides a disease overview, epidemiological insights, current and future treatment practices, and a competitive assessment of marketed and emerging therapies in this domain. The report also highlights the unmet needs with respect to Esophageal Cancer.
Esophageal Cancer is a malignant tumor arising from the inner lining of the esophagus, the tube that connects the throat to the stomach. The two main histological subtypes are squamous cell carcinoma (ESCC), commonly associated with tobacco and alcohol use, and adenocarcinoma (EAC), which is more prevalent in developed regions and strongly linked to chronic gastroesophageal reflux disease (GERD) and Barrett's esophagus. The disease is often aggressive, with a tendency toward late diagnosis due to nonspecific early symptoms, leading to poor prognosis and reduced survival rates. The global burden of Esophageal Cancer is increasing, driven by lifestyle factors, dietary habits, obesity, and aging populations, underscoring the need for early detection and improved therapeutic strategies.

Esophageal Cancer Emerging Drugs Profile
• Zanidatamab: Zymeworks/Jazz Pharmaceuticals
Zanidatamab is a late-stage bispecific HER2-targeted antibody with the potential to transform the standard of care in multiple HER2-expressing cancers, including gastroesophageal adenocarcinoma. It has received Fast Track Designation in combination with standard-of-care chemotherapy for first-line gastroesophageal adenocarcinoma (GEA). Currently, the drug is being evaluated in the Phase III HERIZON-GEA-01 trial in combination with chemotherapy, with or without tislelizumab, for HER2-positive GEA, and carries an anticipated US launch in 2027.
• Bemarituzumab: Amgen
Bemarituzumab targets the FGFR2b receptor to inhibit tumor growth and signaling in FGFR2b-positive gastric and gastroesophageal junction cancers. Currently, the drug is in the Phase III stage of development.
• Telisotuzumab Adizutecan (Temab-A): AbbVie
Telisotuzumab adizutecan is a c-Met-targeting antibody-drug conjugate (ADC) designed to deliver a cytotoxic payload directly to tumor cells in advanced solid tumors. Currently, the drug is in the Phase II stage of development.

Explore groundbreaking therapies and clinical trials in the Esophageal Cancer Market. Access DelveInsight's detailed report now! @ https://www.delveinsight.com/report-store/esophageal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

The Esophageal Cancer Market Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Esophageal Cancer, along with market size and share estimates by therapy.
• It assesses the current and emerging therapeutic candidates segmented into early-stage, mid-stage, and late-stage development for Esophageal Cancer treatment.
• Esophageal Cancer Companies are involved in multimodal and biomarker-driven therapeutics development, spanning chemotherapy, immunotherapy, targeted therapy, and antibody-drug conjugates.
• Esophageal Cancer Drugs under development are assessed based on stage of development, route of administration, target receptor/mechanism of action, and molecule type.
• Detailed epidemiological forecasting, patient burden trends, pricing and reimbursement analysis, KOL views, and SWOT/conjoint analysis for future advancement of the Esophageal Cancer Market.

Esophageal Cancer Companies
Jazz Pharmaceuticals, ZymeWorks, Amgen, Bayer, Eli Lilly and Company, Innovent, BeiGene, Apexigen, AstraZeneca, Bristol-Myers Squibb Company, Merck, AbbVie, and others.

Esophageal Cancer Market Report provides the therapeutic assessment of the pipeline and marketed drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intravenous
• Oral
• Subcutaneous
Esophageal Cancer Products have been categorized under various Molecule types such as
• Monoclonal antibody
• Bispecific monoclonal antibody
• Antibody-drug conjugate
• Small molecule (kinase inhibitor)

Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ https://www.delveinsight.com/report-store/esophageal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Scope of the Esophageal Cancer Market Report
• Coverage- 7MM (US, EU4, UK, Japan)
• Study Period- 2022-2036 (Historical: 2022-2025; Base Year: 2026; Forecast: 2026-2036)
• Esophageal Cancer Companies- Jazz Pharmaceuticals, ZymeWorks, Amgen, Bayer, Eli Lilly and Company, Innovent, BeiGene, Apexigen, AstraZeneca, Bristol-Myers Squibb Company, Merck, AbbVie, and others.
• Esophageal Cancer Therapies- Tislelizumab (TEVIMBRA), Telisotuzumab adizutecan (Temab-A), Durvalumab (IMFINZI), Pembrolizumab (KEYTRUDA), Nivolumab (OPDIVO), Ramucirumab (CYRAMZA), Larotrectinib (VITRAKVI), Zanidatamab, Bemarituzumab, and others.
• Esophageal Cancer Market CAGR (2026-2036)- 6.0%
• Esophageal Cancer Epidemiology Segmentation- Diagnosed Incident Cases, Histology-specific Cases, Gender-specific Cases, Age-specific Cases, Mutation-specific Cases, Stage-specific Cases, Line-wise Treated Cases

Find out in DelveInsight's exclusive Esophageal Cancer Market Report-access it now! @ https://www.delveinsight.com/report-store/esophageal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Table of Contents
1. Introduction
2. Executive Summary
3. Esophageal Cancer: Overview and Diagnosis
4. Epidemiology and Patient Burden Assessment
5. Esophageal Cancer Current Treatment Practices
6. Esophageal Cancer Unmet Needs
7. Esophageal Cancer Marketed/Approved Therapies
8. Esophageal Cancer Pipeline Analysis (Emerging Therapies)
9. Zanidatamab: Zymeworks/Jazz Pharmaceuticals
10. Bemarituzumab: Amgen
11. Telisotuzumab Adizutecan (Temab-A): AbbVie
12. Esophageal Cancer Market Outlook and Drug Uptake
13. Esophageal Cancer Market Access and Reimbursement
14. Esophageal Cancer Therapies Price Scenario & Trends
15. Industry Experts and Physician (KOL) Views
16. Esophageal Cancer Report Qualitative Analysis: SWOT and Conjoint Analysis
17. Esophageal Cancer Market Size and Forecast (2022-2036)
18. Esophageal Cancer Key Companies
19. Esophageal Cancer Market Drivers and Barriers
20. Appendix
21. About Us

Contact Information
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: mmalhotra@delveinsight.com
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.